Nutt D J
Psychopharmacology Unit, University of Bristol, School of Medical Sciences, UK.
J Clin Psychiatry. 1999;60 Suppl 17:23-7; discussion 46-8.
Anxiety frequently coexists with depression, either as a comorbid anxiety disorder or as anxiety symptoms accompanying a primary depressive disorder. Effective therapy for the treatment of depressive illness must include a consideration of anxiety symptoms, since anxiety has been estimated to be present in up to 96% of patients with depressive illness. Available data also indicate that depressed patients with significant anxiety may be at greater risk for suicide. Of particular clinical importance are symptoms of somatic anxiety: they are present in up to 86% of depressed patients, and the failure to treat them effectively can diminish the ability of a patient to function. Since the overall prognosis for recovery from a major depressive episode is less than optimal in patients with significant anxiety, treatments that can provide an effective and early relief of both depressive and anxiety symptoms are of paramount importance. Drugs with serotonin reuptake inhibition (such as selective serotonin reuptake inhibitors [SSRIs] or serotonin-norepinephrine reuptake inhibitors [SNRIs]) may produce transient increases in anxiety symptomatology presenting as jitteriness, agitation, insomnia, and gastrointestinal symptoms when treatment is initiated. Mirtazapine has intrinsic receptor-blocking properties (in particular, serotonin-2 [5-HT2] receptor blockade) that can be linked to an early relief of anxiety symptoms during the treatment. The available data show that mirtazapine is superior to placebo in depressed patients with high baseline anxiety and/or agitation. Furthermore, mirtazapine was statistically significantly superior to both citalopram and paroxetine in alleviating anxiety symptoms early in treatment as assessed by changes from baseline on the Hamilton Rating Scale for Anxiety or the Hamilton Rating Scale for Depression anxiety/somatization factor, respectively. Mirtazapine provides early and effective relief of both depressive and anxiety symptoms, reducing the need for polypharmacy. These therapeutic actions of mirtazapine persist throughout the course of treatment.
焦虑常常与抑郁并存,既可能是共病的焦虑症,也可能是原发性抑郁症伴随的焦虑症状。治疗抑郁症的有效疗法必须考虑到焦虑症状,因为据估计,高达96%的抑郁症患者存在焦虑症状。现有数据还表明,伴有严重焦虑的抑郁症患者自杀风险可能更高。特别具有临床重要性的是躯体焦虑症状:高达86%的抑郁症患者存在此类症状,若不能有效治疗,会削弱患者的功能。由于伴有严重焦虑的患者从重度抑郁发作中康复的总体预后欠佳,能够有效且早期缓解抑郁和焦虑症状的治疗方法至关重要。具有5-羟色胺再摄取抑制作用的药物(如选择性5-羟色胺再摄取抑制剂[SSRI]或5-羟色胺-去甲肾上腺素再摄取抑制剂[SNRI])在开始治疗时可能会使焦虑症状短暂加重,表现为紧张不安、激动、失眠和胃肠道症状。米氮平具有内在的受体阻断特性(特别是5-羟色胺-2[5-HT2]受体阻断),这可能与治疗期间焦虑症状的早期缓解有关。现有数据表明,在基线焦虑和/或激动程度较高的抑郁症患者中,米氮平优于安慰剂。此外,分别根据汉密尔顿焦虑量表或汉密尔顿抑郁量表焦虑/躯体化因子从基线的变化评估,米氮平在治疗早期缓解焦虑症状方面在统计学上显著优于西酞普兰和帕罗西汀。米氮平能早期且有效地缓解抑郁和焦虑症状,减少联合用药的需求。米氮平的这些治疗作用在整个治疗过程中持续存在。